FDA 483 - Ipca Laboratories Limited - December 05, 2025

An FDA inspection conducted at Ipca Laboratories Limited from December 1 to December 5, 2025, identified three significant observations related to manufacturing practices for Active Pharmaceutical Ingredients (APIs) destined for the US market. The findings, detailed in an FDA 483 document, highlight deficiencies in facility maintenance, analytical test methods, and controls to prevent material cross-contamination.

Specifically, Observation 1 noted that manufacturing clean rooms were not adequately maintained to minimize potential contamination. Examples included significant peeling paint on ceilings and numerous cracks on walls and ceilings in areas where APIs are exposed, indicating a failure to address these issues despite routine facility inspections.

Observation 2 addressed deficiencies in the suitability of analytical test methods. The verification studies for HPLC assays and organic impurities were found to be inadequate, particularly regarding unvalidated column temperature ranges. This concern was underscored by a previous out-of-specification investigation that revealed issues with shifted peak retention times, questioning method reliability.

Finally, Observation 3 pointed to a lack of adequate controls to minimize residual material carryover between successive batches of the same API. The company's procedures did not establish a maximum duration for manufacturing campaigns, and no scientific data was provided to assure that residual materials from previous batches were not carried over into subsequent ones.

These observations indicate non-compliance with established Good Manufacturing Practices, requiring Ipca Laboratories Limited to implement comprehensive corrective and preventive actions to ensure product quality and safety, and formally respond to the FDA addressing each finding.